SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending amid significant community frustration as the biotech sector's sustained rally defies bearish expectations, with many speculating on market manipulation and technical divergences while others anticipate an imminent reversal for the XBI.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is trending as cybersecurity stocks respond to the emergence of new AI code security tools, fueling community debate over potential disruption versus the significant new growth opportunity for Okta in securing AI agents and digital identities.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

The biotech sector, tracked by LABU's underlying index XBI, is rallying strongly, driven by recent M&A activity like the Biomarin buyout and persistent optimism for AI's transformative role in drug discovery. While some caution about stretched technicals, the community is keenly discussing a potential sustained "catch-up rally" for biotech, further buoyed by anticipated rate cuts benefiting growth sectors.

SSgA Active Trust - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

The Financial Select Sector SPDR Fund (XLF) is trending due to widespread technical weakness and a prevailing bearish sentiment, with community discussion highlighting a potential major breakdown and eyeing key support levels. Concerns over broader economic health, including consumer delinquencies, and policy discussions like potential credit card rate caps, are contributing to a cautious outlook despite mixed bank earnings reports.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

The community is actively debating Pi Network's prolonged mainnet launch, with widespread frustration over unresolved KYC and coin migration issues, compounded by its absence from major crypto exchanges. Despite some pioneers maintaining long-term bullish sentiment, many users express skepticism, questioning its real-world utility and likening the project to an ad revenue scheme.

Bombardier Cl B Sv

Bombardier is a major talking point as the market reacts to potential US tariff threats against Canadian goods, though many in the community believe the company's business jets may be exempt under trade agreements or can navigate any new duties. This uncertainty contrasts with strong underlying financials and future growth prospects driven by new aircraft orders, defense opportunities, and consistent delivery performance, fueling investor frustration over recent share price volatility.

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Aktis Oncology Inc

Akoustis Technologies Inc

Akoustis Technologies Inc. is trending as it navigates bankruptcy proceedings and the sale of its assets, with the community largely expecting a wipeout for original shareholders. Compounding the conversation, the AKTS ticker is concurrently associated with Aktis Oncology, a newly IPO'd radiopharmaceutical company that has seen strong interest following a notable investment from Eli Lilly and a significant market debut.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is seeing heightened community discussion around its new Indensity battery storage system, a potential game-changer for AI data center power needs and grid modernization, as investors weigh its unique U.S.-made technology against lingering execution concerns ahead of an imminent earnings report.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is trending as the community eagerly discusses its recently announced token buyback, fueling expectations for significant upside given its low market cap and foundational role in decentralized internet infrastructure and secure Web3 communication.

ATI, Inc. engages in the manufacture of specialty materials and components. It operates through the High Performance Materials and Components and Advanced Alloys and Solutions segments. The High Performance Materials and Components segment consists of the production of materials, parts, and components for aerospace and defense, medical, and energy markets. The Advanced Alloys and Solutions segment includes the production of nickel-based alloys, titanium and titanium-based alloys, and alloys in a variety of forms including plate, sheet, and PRS products. The company was founded on August 15, 1996 and is headquartered in Dallas, TX.

ATI Inc

Allegheny Technologies Inc

Strong demand in the aerospace and defense sectors for Allegheny Technologies' (ATI) specialty materials and a substantial new share repurchase program are fueling investor conversation. The community is highlighting the stock's impressive price momentum and its strategic position in securing the domestic titanium supply chain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200 Day Moving Average - Here's Why

Assembly Biosciences (NASDAQ:ASMB) Shares Cross Above 200 Day Moving Average - Time to Sell...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat Ratings reports. One...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of "Moderate Buy" from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are covering the firm, MarketBeat Ratings reports. One...

Assembly Biosciences (NASDAQ:ASMB) Trading 4% Higher - Here's What Happened

Assembly Biosciences (NASDAQ:ASMB) Trading 4% Higher - Here's What Happened...

Ellsworth Advisors LLC Acquires New Holdings in Assembly Biosciences, Inc. $ASMB

Ellsworth Advisors LLC bought a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) during the third quarter, according to the company in its most recent 13F filing with the...

Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6% - What's Next?

Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6% - Should You Sell...

GILD Exercises Option to License Assembly Bio's Herpes Programs

Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.

<ul class="summary-bullets"><li>Gilead will advance the clinical development and commercialization of the programs and Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option.</li><li>H.C. Wainwright believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."</li><li>According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes.</li></ul>Shares of Assembly Biosciences Inc closed up 3% on Monday after Gilead Sciences exercised the option to license the company’s programs for recurrent genital herpes in a move applauded by Wall Street. &nbsp;The programs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.gilead.com/news/news-details/2025/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes"> include</a> investigational candidates ABI-1179 and ABI-5366. Gilead will advance the clinical development and commercialization of the programs under its ongoing collaboration with Assembly Bio which was inked in 2023 and spans 12 years. Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option and remains eligible for up to $330 million in regulatory and commercial milestones, as well as tiered royalties on net sales.H.C. Wainwright analyst Patrick Trucchio subsequently reiterated a ‘Buy’ rating on Assembly Biosciences (ASMB) with a $50 price target. The analyst believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."<h2 class="st-heading-2">About The Programs</h2>Genital herpes is a common sexually transmitted infection (STI) caused by the herpes simplex virus (HSV), leading to painful blisters and sores around the genitals or anus, though many people have mild or no symptoms and don't know they're infected. Spread through skin-to-skin contact, especially during sex, the virus stays in the body, causing recurring outbreaks triggered by stress, illness, or fatigue.According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes. No new therapies have been approved for HSV in the U.S. or Europe for more than 25 years, the company noted.ABI-1179 and ABI-5366 are novel long-acting inhibitors of viral helicase-primase, an enzyme essential for herpes virus replication. Positive interim Phase 1b data for ABI-5366 and ABI-1179 demonstrated strong antiviral activity and improvements in clinical outcomes, including significant reduction in virus-positive lesions, the company noted. Both compounds also exhibit pharmacokinetic and safety profiles supportive of once-weekly oral dosing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/ASMB"> ASMB </a>rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.Sentiment around GILD stayed within the 'neutral' territory in the meantime.<a href="https://stocktwits.com/symbol/GILD">Shares of GILD</a> have risen nearly 34% this year while ASMB shares have more than doubled.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-rival-ula-ceo-tory-bruno-steps-down/cLeFtcyREub">SpaceX Rival ULA CEO Tory Bruno Steps Down After 12 Years — Says ‘My Work Here Is Now Complete’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs

Gilead Sciences exercised the option to license Assembly Biosciences’ programs for recurrent genital herpes, including investigational candidates ABI-1179 and ABI-5366.

Equity

Gilead Sciences exercised the option to license Assembly Biosciences’ programs for recurrent genital herpes, including investigational candidates ABI-1179 and ABI-5366.


Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading Volume - Should You Buy?

Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading Volume - What's Next...

Assembly Biosciences' (ASMB) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Assembly Biosciences in a report on Monday...

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

ASMB
Assembly Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ASMB News

ASMBAssembly Biosciences Inc